Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful ...

A group from Nagoya University in Japan has developed a simple, accurate, and sensitive method for measuring polysialic acid, ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

Jacobio Pharma submits phase I/II IND application for its BET inhibitor, JAB-8263 to treat autoimmune diseases to CDE in China: Beijing, Shanghai Friday, July 4, 2025, 13:00 Hrs [ ...

"Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma" was originally created and published by ...

A delay, as opposed to a firm stagnation, then, but one unfolding over several years. This applies not only to SMEs, but to big pharma, too, in terms of restructuring and refocusing – even in terms of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...